CN113521016A - 抗体-药物缀合物冻干制剂 - Google Patents

抗体-药物缀合物冻干制剂 Download PDF

Info

Publication number
CN113521016A
CN113521016A CN202110607250.1A CN202110607250A CN113521016A CN 113521016 A CN113521016 A CN 113521016A CN 202110607250 A CN202110607250 A CN 202110607250A CN 113521016 A CN113521016 A CN 113521016A
Authority
CN
China
Prior art keywords
region
seq
amino acid
acid sequence
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110607250.1A
Other languages
English (en)
Chinese (zh)
Inventor
J.瓦布乔恩
X.京
K.A.罗拜
T.W.鲍尔
G.A.萨查
N.A.皮塞
B.维鲁姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of CN113521016A publication Critical patent/CN113521016A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202110607250.1A 2013-11-21 2014-11-21 抗体-药物缀合物冻干制剂 Pending CN113521016A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907001P 2013-11-21 2013-11-21
US61/907001 2013-11-21
CN201480073804.2A CN106163567B (zh) 2013-11-21 2014-11-21 抗体-药物缀合物冻干制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480073804.2A Division CN106163567B (zh) 2013-11-21 2014-11-21 抗体-药物缀合物冻干制剂

Publications (1)

Publication Number Publication Date
CN113521016A true CN113521016A (zh) 2021-10-22

Family

ID=51947368

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480073804.2A Active CN106163567B (zh) 2013-11-21 2014-11-21 抗体-药物缀合物冻干制剂
CN202110607250.1A Pending CN113521016A (zh) 2013-11-21 2014-11-21 抗体-药物缀合物冻干制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201480073804.2A Active CN106163567B (zh) 2013-11-21 2014-11-21 抗体-药物缀合物冻干制剂

Country Status (15)

Country Link
US (3) US10617764B2 (enExample)
EP (2) EP3071237B1 (enExample)
JP (3) JP6590803B2 (enExample)
KR (1) KR102372245B1 (enExample)
CN (2) CN106163567B (enExample)
DK (1) DK3071237T3 (enExample)
ES (1) ES2983564T3 (enExample)
FI (1) FI3071237T3 (enExample)
HR (1) HRP20241036T1 (enExample)
HU (1) HUE068207T2 (enExample)
MX (1) MX377841B (enExample)
PL (1) PL3071237T3 (enExample)
PT (1) PT3071237T (enExample)
SI (1) SI3071237T1 (enExample)
WO (1) WO2015075201A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56599B1 (sr) * 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
JP6590803B2 (ja) * 2013-11-21 2019-10-16 ゲンマブ エー／エス 抗体−薬物コンジュゲート凍結乾燥製剤
JP6522806B2 (ja) * 2015-07-10 2019-05-29 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 抗体デュオカルマイシン薬物複合体を含む組成物
US20190030178A1 (en) 2015-09-11 2019-01-31 Genmab A/S Dosing regimens for anti-tf-antibody drug-conjugates
FI3380525T3 (fi) 2015-11-25 2024-01-30 Immunogen Inc Lääkeformulaatioita ja niiden käyttömenetelmiä
KR20180101479A (ko) * 2016-01-13 2018-09-12 젠맵 에이/에스 항체 및 그의 약물 접합체를 위한 제제
HRP20210945T1 (hr) 2016-06-27 2021-09-17 Morphosys Ag Formulacije protutijela anti-cd19
CN106938051B (zh) * 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
BR112020013679A2 (pt) 2018-01-04 2020-12-01 Iconic Therapeutics, Inc. anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CR20250325A (es) * 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
BR112020022265A2 (pt) 2018-05-07 2021-02-23 Genmab A/S método para tratar câncer em um indivíduo, e, estojo.
CN112739716B (zh) 2018-05-07 2025-05-27 展马博联合股份有限公司 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
MX2021001058A (es) * 2018-08-16 2021-04-12 Genmab As Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer.
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
MX2022001719A (es) * 2019-08-15 2022-03-11 Silverback Therapeutics Inc Formulaciones de conjugados de benzazepina y usos de las mismas.
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
CA3155754A1 (en) 2019-11-07 2021-05-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EP4171652A1 (en) 2020-06-29 2023-05-03 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CN116635077A (zh) * 2020-11-10 2023-08-22 赛诺菲 Ceacam5抗体-药物缀合物制剂
CA3231134A1 (en) * 2021-09-08 2023-03-16 Coherent Biopharma (Suzhou) Limited Pharmaceutical preparation, preparation method therefor and use thereof
TW202327659A (zh) * 2021-10-19 2023-07-16 大陸商同宜醫藥（蘇州）有限公司 偶聯體藥物製劑及其製備方法和用途
US20250302982A1 (en) 2022-05-06 2025-10-02 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
CN117045634B (zh) * 2022-05-06 2025-10-10 北京康蒂尼药业股份有限公司 一种二肽衍生物组合物及其制备方法和用途
WO2024083162A1 (en) 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof
CN115656496A (zh) * 2022-10-28 2023-01-31 迪瑞医疗科技股份有限公司 一种普适型冻干保护剂及其应用
TW202448934A (zh) * 2023-04-28 2024-12-16 大陸商江蘇恆瑞醫藥股份有限公司 抗tf抗體和抗tf抗體-藥物偶聯物及其醫藥用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101237881A (zh) * 2005-08-03 2008-08-06 免疫基因公司 免疫偶联物剂型
CN103119065A (zh) * 2010-06-15 2013-05-22 根马布股份公司 针对组织因子的人抗体药物缀合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP3919235B2 (ja) 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20060246060A1 (en) 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2007034443A (ja) * 2005-07-22 2007-02-08 Konica Minolta Business Technologies Inc 画像形成システム、画像形成装置及び画像形成処理方法
BRPI0614100A2 (pt) 2005-08-03 2011-03-09 Immunogen Inc formulações de imunoconjugado lìquidas
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AU2008269179A1 (en) 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
KR20090001217A (ko) * 2007-06-29 2009-01-08 삼성전자주식회사 미싱 노즐 검출방법 및 이를 이용하는 잉크젯 프린트 헤드
JP4824710B2 (ja) * 2008-02-08 2011-11-30 国立清華大学 グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5005023B2 (ja) * 2009-12-25 2012-08-22 インターナショナル・ビジネス・マシーンズ・コーポレーション 読出し及び書込み命令の混在するコマンド列を受け取った場合の最適な書込みを実行するリニア記録方式の装置、その方法、及びプログラム。
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
CA2792125C (en) * 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
JP6590803B2 (ja) * 2013-11-21 2019-10-16 ゲンマブ エー／エス 抗体−薬物コンジュゲート凍結乾燥製剤
US20190030178A1 (en) 2015-09-11 2019-01-31 Genmab A/S Dosing regimens for anti-tf-antibody drug-conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101237881A (zh) * 2005-08-03 2008-08-06 免疫基因公司 免疫偶联物剂型
CN103119065A (zh) * 2010-06-15 2013-05-22 根马布股份公司 针对组织因子的人抗体药物缀合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.L. ROY等: "The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory", 《DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION》 *
TRACY T. CHEN等: "Development of a stable lyophilized formulation for a monoclonal antibody-doxorubicin conjugate", 《PHARMACEUTICAL RESEARCH》 *

Also Published As

Publication number Publication date
WO2015075201A1 (en) 2015-05-28
MX377841B (es) 2025-03-11
EP4420729A2 (en) 2024-08-28
JP2021119199A (ja) 2021-08-12
BR112016011441A2 (pt) 2017-09-26
ES2983564T3 (es) 2024-10-23
FI3071237T3 (fi) 2024-09-23
HRP20241036T1 (hr) 2024-11-08
EP4420729A3 (en) 2024-10-30
JP6590803B2 (ja) 2019-10-16
SI3071237T1 (sl) 2024-11-29
EP3071237A1 (en) 2016-09-28
JP7162695B2 (ja) 2022-10-28
KR20160079890A (ko) 2016-07-06
PT3071237T (pt) 2024-08-26
US20200246477A1 (en) 2020-08-06
MX2016006488A (es) 2016-08-03
US20240091373A1 (en) 2024-03-21
KR102372245B1 (ko) 2022-03-08
CN106163567A (zh) 2016-11-23
CN106163567B (zh) 2021-06-11
JP2019163319A (ja) 2019-09-26
DK3071237T3 (da) 2024-09-09
US20160279258A1 (en) 2016-09-29
EP3071237B1 (en) 2024-06-26
HUE068207T2 (hu) 2024-12-28
US10617764B2 (en) 2020-04-14
PL3071237T3 (pl) 2024-12-02
JP2016539118A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
US20240091373A1 (en) Antibody-drug conjugate lyophilised formulation
JP6521959B2 (ja) 操作されたポリペプチドコンジュゲート
CN109496149B (zh) 抗体及其药物缀合物的制剂
TW200831133A (en) Mab Abeta lyophylized formulation
KR20160141726A (ko) 항-cd19 항체 및 항체-약물 컨쥬게이트에 대한 안정한 제형
US20230414760A1 (en) Pharmaceutical formulation
TW201713363A (zh) 卡奇黴素構建體及使用方法
TW201902518A (zh) 一種含c-Met抗體藥物偶聯物的醫藥組成物及其用途
HK40059296A (en) Antibody-drug conjugate lyophilised formulation
US20250108122A1 (en) Pharmaceutical composition comprising anti-cd79b antibody-drug conjugate and use thereof
US20250312470A1 (en) A pharmaceutical composition of anti-her2 antibody-immune agonist conjugate and applications thereof
HK1229256B (en) Antibody-drug conjugate lyophilised formulation
HK1229256A1 (en) Antibody-drug conjugate lyophilised formulation
BR112016011441B1 (pt) Formulação liofilizada, solução aquosa, e, métodos para preparar uma formulação liofilizada e uma solução injetável
HK40000543B (en) Formulation for antibody and drug conjugate thereof
HK40000543A (en) Formulation for antibody and drug conjugate thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059296

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Denmark

Address after: DanMai Val Be

Applicant after: GENMAB A/S

Address before: Tanba Goro haro

Applicant before: GENMAB A/S

Country or region before: Denmark